Sugar-Functionalized Nucleic Acid Carriers for Low-Toxicity Transfection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing nucleic acid delivery systems face challenges in achieving high cellular uptake, biocompatibility, low toxicity, and high transfection efficiency, necessitating a balance that current non-viral carriers fail to meet.
Innovation Solution
Development of sugar-functionalized nanoparticle compositions comprising nucleic acid carriers with amine linkers, hydrophobic units, and deoxy sugars, optionally with conjugated lipids and phospholipids, to enhance intracellular delivery and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If non-viral nucleic acid carriers are used, then biocompatibility and low toxicity are improved, but cellular uptake and transfection efficiency deteriorate
Solution Approach 1:
The patent employs composite nanoparticle structures combining multiple functional components: cationic polymers for nucleic acid binding, PEGylated lipids for biocompatibility and stealth properties, and targeting ligands for enhanced cellular uptake. This composite approach allows simultaneous achievement of low toxicity and high transfection efficiency by integrating the advantages of different material classes into a single delivery system.
Solution Approach 2:
The patent systematically optimizes critical parameters including polymer molecular weight, charge density, PEG chain length, and lipid composition ratios to balance biocompatibility and transfection efficiency. By adjusting these parameters, the formulation achieves the desired therapeutic window where sufficient cellular uptake occurs without excessive toxicity.
2Object-affected harmful factors
If non-viral nucleic acid carriers are used, then biocompatibility is improved, but cellular uptake deteriorates
Solution Approach 1:
The patent applies local quality modification by incorporating specific functional domains within the nanoparticle structure: cationic regions for nucleic acid condensation, PEGylated regions for biocompatibility and extended circulation, and surface-exposed targeting ligands for enhanced cellular recognition and uptake. Each region performs its specific function locally while contributing to overall system performance.
Solution Approach 2:
The patent uses PEGylated lipids as intermediary components that mediate between the cationic polymer core and the biological environment. These PEGylated intermediaries provide biocompatibility and steric stabilization while allowing the cationic core to maintain its nucleic acid binding and cellular interaction capabilities.
3Productivity
If high loading capacity is achieved, then delivery efficiency is improved, but biocompatibility deteriorates
Solution Approach 1:
The patent employs a nested structure where nucleic acids are condensed within a polymeric core, which is then encapsulated by a lipid bilayer containing PEGylated components. This nested architecture allows high nucleic acid loading capacity in the inner core while the outer lipid layer provides biocompatibility and controls interaction with biological systems, effectively shielding the potentially toxic cationic polymer.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle compositions demonstrate improved cellular uptake, biocompatibility, and transfection efficiency, facilitating effective delivery of therapeutic or immunogenic nucleic acids for disease treatment and prevention.
Implementation Method 1
A is an amine linker
Implementation Method 2
B is a hydrophobic unit
Data Source
AI summary
Nanoparticle compositions for delivery of nucleic acids to subjects including carriers comprising sugar functionalized nucleic acid carriers, and therapeutic or immunogenic nucleic acid agents enclosed within the delivery molecules are described. Methods for treating or preventing diseases or conditions in a subject by administering the nanoparticle compositions that provide immune responses and synergistic therapeutic or preventive effects are provided.